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Abstract
While amyloid formation has been implicated in the pathology of over twenty human diseases, the 
rational design of amyloid inhibitors is hampered by a lack of structural information about 
amyloid-inhibitor complexes. We use isotope labeling and two-dimensional infrared spectroscopy 
to obtain a residue-specific structure for the complex of human amylin, the peptide responsible for 
islet amyloid formation in type 2 diabetes, with a known inhibitor, rat amylin. Based on its 
sequence, rat amylin should block formation of the C-terminal β-sheet, but at 8 hours after mixing 
rat amylin blocks the N-terminal β-sheet instead. At 24 hours after mixing, rat amylin blocks 
neither β-sheet and forms its own β-sheet most likely on the outside of the human fibrils. This is 
striking because rat amylin is natively disordered and not previously known to form amyloid β-
sheets. The results show that even seemingly intuitive inhibitors may function by unforeseen and 
complex structural processes.
INTRODUCTION
There is great interest in developing inhibitors of protein aggregation and amyloid formation 
as a means of combating Alzheimer’s disease, Parkinson’s disease, type 2 diabetes, and 
other human diseases1–3. Many types of inhibitors have been investigated, but the most 
common are small molecules4,5 and peptides6–13. A common strategy for designing peptide 
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or peptide-mimic inhibitors involves two features6,8,13: (a) high sequence similarity with one 
region of the target protein to promote binding and (b) mutations in a second region so as to 
destabilize or prevent the formation of fibrils or oligomers. Mutations often include 
unnatural amino acids6,7,9, or natural amino acids such as proline, that act as β-sheet 
blockers11,12.
A range of peptide inhibitors have been developed against human amylin8–12 (islet amyloid 
polypeptide or IAPP) the causative agent of islet amyloid in type 2 diabetes. While it is 
straightforward to test whether an inhibitor prevents fibril formation in vitro, without 
detailed structural information, it is very difficult to determine why some potential inhibitors 
are effective and others fail. For example, rat amylin has many of the features that one 
utilizes in inhibitor design including sequence similarity to human amylin and β-blocking 
proline residues (see Fig. 1a). It also does not form fibrils under any previously known 
conditions and rats do not get type 2 diabetes. Indeed, the rat amylin sequence has been used 
as the basis for designing an FDA-approved hypoglycemic agent for diabetics14. But in 
practice, rat amylin is only a moderately effective inhibitor; it must be present in ~10-fold 
excess to strongly inhibit human amylin fibril formation. With equimolar rat amylin (the 
ratio used in this study) 10–15% fewer fibrils are formed and the lag time for fibril 
formation is increased roughly two fold12. It is difficult to rationally improve the 
effectiveness of rat amylin because there is no structural information on the human amylin-
inhibitor complex, at any point in the aggregation process, to guide design.
Rat amylin has been shown to inhibit amyloid formation by human amylin using thioflavin-
T fluorescence, circular dichroism spectroscopy, and transmission electron microscopy 
(TEM)12, which are methods that are widely employed in inhibitor studies. However, these 
techniques do not provide sufficient structural information to determine the binding. 
Mutagenesis, thermodynamics and other approaches can together provide considerable 
insight into inhibitor mechanisms15–17. Solid-state NMR18,19 and molecular dynamics 
simulations20 have been used to study inhibitor binding to some amyloid fibrils and X-ray 
structures of amyloids formed from short peptides have been used to design inhibitors21. 
These relatively few studies are a testament to the difficulty of obtaining atomic or even 
residue-level structural information on inhibitor binding.
Here we use isotope labeling and two-dimensional infrared (2D IR) spectroscopy to study 
the structure of an amylin-inhibitor complex with residue-level resolution. Structural models 
of human amylin fibrils reveal that they are made up of columns of U-shaped peptides (Fig. 
1b) that form in-register parallel β-sheets. Each column has a C-terminal β-sheet (residues 
~25 to 37) and an N-terminal β-sheet (residues 8 to ~17) that are separated by a partially 
ordered loop (residues ~18 and ~22)22,23. Between 2 and 5 columns of peptides form a 
fibril, depending on the preparation conditions22,24. A key feature of the structure is the in-
register parallel β-sheet geometry, which is ideally suited for study by IR spectroscopy. If a 
backbone carbonyl is labeled with a 13C18O isotope, a linear column of vibrationally 
coupled residues is created in the fibril (Fig. 1c). The frequency of a linear column of 
coupled oscillators is shifted from the intrinsic vibrational frequency by twice the coupling 
strength25,26. We previously used these frequency shifts to study the residue-specific 
aggregation kinetics of amylin27. In this paper, we use the frequency shifts to determine the 
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binding site of the inhibitor. We also show that the inhibitor remodels the fibril into a 
structure not previously observed. The results are striking because rat amylin forms its own 
β-sheets, most likely on the exterior of the human amylin fibrils, in a dynamic process that is 
not evident from thioflavin-T fluorescence kinetics or from TEM measurements. The 
experiments reveal that inhibition, even for seemingly intuitively designed inhibitors, can be 
a complex process with details that require both structural and temporal resolution to 
uncover.
RESULTS AND DISCUSSION
Isotope Labeling Strategy
To assess the structure at each residue, we perform two control measurements without 
inhibitor. The control experiments account for site-to-site frequency variations caused by 
effects other than β-sheet formation, such as hydrogen bonding, environment electrostatics, 
and structural disorder. For each site, we first measure the spectrum of a sample in which 
only 25% of the peptides are labeled. At 25% dilution, only ~5% of labels form columns 
longer than three labels (see Supplemental). Thus, isotopic dilution eliminates the linear 
columns of labels so that the peak maximum provides the zero-coupling frequency for the 
site. We then measure the spectrum of a sample in which 100% of the peptides are labeled, 
providing the fully coupled frequency for the site. Two residues, Ala5 and Ser20, are in 
disordered regions of the fibril and did not exhibit a frequency difference (Supplementary 
Fig. S1). However, in most cases, the frequency difference between the pure-labeled and 
dilute-labeled samples gives the frequency shift caused by the coupling, which is directly 
related to structure25.
Finally, we measure the spectrum of 100% labeled human amylin and unlabeled rat amylin, 
mixed as monomers at equimolar concentrations and matured together. Comparison of the 
mixed spectra with the two control spectra reveals the extent to which the inhibitor reduces 
the frequency shift. If the frequency shift remains appreciably negative or is unchanged, then 
the β-sheet is intact at this site. If the frequency shift is lost then the inhibitor has disrupted 
the β-sheet at this position. Therefore, isotope labeling provides a direct, site-specific, non-
perturbing probe of the degree to which the inhibitor disrupts β-sheet structure in the amylin-
inhibitor complex.
Structure of the Amyloid-Inhibitor Complex
Since thioflavin-T kinetics suggest that the amylin-inhibitor complex is equilibrated by 8 
hours (Supplementary Fig. S2), we collected 2D IR spectra at 8 and 24 hours after mixing. 
At 8 hours, sets of 2D IR spectra were collected for 9 residues, chosen because they are 
spaced throughout the amylin sequence (Fig. 1b). Shown in Fig. 2 are spectra for residues 
Ala13, Leu16, Ala25 and Leu27. Ala13 has one of the largest frequency shifts, from 1598 
cm−1 in the dilute-labeled spectrum (Fig. 2c) to 1580 cm−1 in the pure-labeled spectrum 
(Fig. 2a). This shift indicates that Ala13 resides in a highly ordered β-sheet25,26, which is 
consistent with the solid-state NMR model of the fibril22. When mixed with the inhibitor, 
the Ala13 frequency shift is absent (Fig. 2b) indicating that Ala13 residues are now 
uncoupled. Similar observations are made by comparing the three spectra for Leu16 (Figs. 
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2d–f) and Ala8 (Supplementary Fig. S3). These results indicate that the N-terminal β-sheet 
structure is altered or eliminated by the inhibitor at these sites.
The inhibitor does not disrupt the coupling for all the measured residues. The spectra for two 
other labels, Ala25 and Leu27, are shown in Figs. 2g–l. For Leu27, there is a 20 cm−1 shift 
between the pure-labeled (Fig. 2l) and dilute-labeled (Fig. 2j) human amylin samples. The 
label frequency is still shifted by 12 cm−1 in the amylin-inhibitor complex. Thus, the 
coupling is diminished by 40% at Leu27, but is still very large. For Ala25, the frequency 
shift is unchanged in the presence of the inhibitor indicating that the inhibitor has not 
disrupted the ordered network of coupled sites. We also observed that coupling was retained 
for Val32 and Gly33 (Supplementary Fig. S3). These data show that the C-terminal β-sheet 
structure of the complex is highly similar to that of human fibrils.
Fig. 1b summarizes the results by plotting the outcome for each residue in relation to its 
position in the fibril structure. Residues for which the inhibitor eliminated the coupling are 
located in the N-terminal β-sheet of the amylin-inhibitor complex whereas residues for 
which the inhibitor had little or no effect lie in the C-terminal β-sheet. The results are 
summarized numerically in Table S1 and are reproducible (Supplementary Fig. S4–S7). The 
absence of excitonic coupling in the N-terminus suggests that rat amylin prevents formation 
of the exterior β-sheets in the amylinin-hibitor complex (Fig. 3a), but does not rule out the 
possibility that human-rat amylin β-sheets are formed (Fig. 3b). Mixed β-sheets seem likely 
since rat and human amylin have identical sequences in their first 17 residues and because 
fragments (residues 8–20) of both rat and human amylin are capable of forming fibrils on 
their own28. Thus either could contribute to forming the N-terminal β-sheet. However, 2D 
IR (Fig. 3c) and circular dichroism12 spectra of the amylin-inhibitor complex compared with 
an equimolar mixture of rat amylin monomers and preformed human amylin fibrils, indicate 
that the complex contains less β-sheet and is more disordered than the canonical fibril.
To more precisely test whether the N-terminal of rat amylin replaces human amylin in the 
fibril structure, we isotope labeled Ala13 in both the rat and human peptides. 2D IR spectra 
are shown in (Figs. 3e–f). We find that the coupling at Ala13 is not restored in the complex 
when both rat amylin and human amylin are labeled. This lack of coupling eliminates the 
possibility of in-register mixed human-rat β-sheets, even though the N-terminal sequences of 
the two peptides are identical. Design principles would suggest that the similarity of the rat 
and human N-terminal sequences would promote binding to the N-terminal region while the 
prolines in rat amylin would prevent formation of the C-terminal β-sheet, but these structural 
studies show that rat amylin prevents the N-terminal β-sheet instead.
Long-term Structural Dynamics
All of the spectra reported above were collected 8 hours after mixing human amylin with the 
inhibitor. Eight hours was chosen because thioflavin-T fluorescence measurements indicate 
that the amylin-inhibitor complex has equilibrated by that time (Supplementary Fig. S2). 
However, 2D IR spectra collected 24 hours after mixing show that this is not the case. At 24 
hours, the unlabeled β-sheet feature is more intense than at 8 hours (Fig. 3d) and significant 
excitonic coupling is detected between the Ala13-labeled human amylin peptides, which 
was absent at 8 hours (Fig. 2b vs. 3g), indicating that the N-terminal β-sheet is now formed. 
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One might assume that as the fibril fully forms, the inhibitor diffuses into solution and 
reverts back to its disordered monomeric structure, but that is not the case. At 24 hours, 
excitonic coupling is now present between Ala13-labeled rat amylin peptides (Fig. 3h). 
Therefore, rat amylin itself has also formed amyloidogenic parallel β-sheets. The formation 
of rat amylin β-sheets is unexpected because rat amylin does not form fibrils on its own 
(Supplementary Fig. S8, Ref. 12), or when added to preformed human amylin fibrils 
(Supplementary Fig. S9, Ref. 12) or in the presence of membrane bilayers30–32. We 
hypothesize that the exposed N-terminal region of human amylin in the amylin-inhibitor 
complex promotes the formation of rat amylin β-sheets by providing a template for the 
proper conformation and alignment of the rat amylin N-terminal region. Since the 2D IR 
data provides information on which residues form β-sheets, but not the number or stacking 
arrangement of the β-sheets in the fibrils, we also collected TEM images to probe fibril 
morphologies.
Human amylin fibrils prepared under our conditions produce long fibrils with a width of ~7 
nm (Supplementary Fig. S10), which is consistent with previous studies using similar 
preparation protocols22,24. At 8 hours, TEM images of samples prepared with inhibitor show 
bundles of short fibrils with a large distribution of widths and a mode of ~13 nm (Fig. 4b 
and Supplementary Fig. S10). From our 2D IR data, we know that these structures have 
intact C-terminal β-sheets and denatured N-terminal β-sheets. We hypothesize that the 
denatured β-sheets promote the association of protofibrils into fibrils. At 24 hours, when 
both the human C- and N-terminal β-sheets are formed, the bundles are mostly replaced by 
long fibrils (Fig. 4c and Supplementary Fig. S10) with widths that approach those of pure 
human amylin fibrils (Fig. 4d and Supplementary Fig. S10). The rat amylin β-sheets may be 
forming on the exteriors of the human fibrils, since the fibril widths at 24 hours are slightly 
larger than for purely human fibrils at the same time, although other polymorphic structures 
cannot be ruled out nor can small structures that are not resolved by TEM. Nonetheless, the 
TEM images support the conclusion derived from the 2D IR studies that large structural 
changes occur between 8 to 24 hours even though thioflavin-T assays suggest that the 
system has equilibrated.
The model shown in Fig. 4e is consistent with our experimental data. Rat amylin interacts 
with human monomers or early stage oligomers, as indicated by a lengthening of the lag 
phase (Supplementary Fig. S2, Ref. 12). Mutation studies suggest that N-terminal residues 
are critical for these interactions12. Rat amylin initially inhibits the formation of the N-
terminal β-sheets, but as time progresses, undergoes structural changes that allow the 
canonical human fibril structure to form. In doing so, the inhibitor peptides assemble into 
their own parallel β-sheets on the sides of the fibrils. Our illustration includes only one 
column of human peptides, but according to the TEM data, the bundles must consist of 2 or 
more columns of human amylin peptides. Since fully formed human amylin fibrils do not 
cause rat amylin to aggregate, it must be a transient complex that serves as a seed for rat 
amyloid β-sheet formation.
To explore the hypothesis that the amylin-inhibitor complex can promote the formation of 
rat amylin β-sheets, we used molecular dynamics simulations of one of the polymorphs 
derived from solid-state NMR data by Tycko et al.22 The fibril consists of 10 amylin 
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peptides stacked into two columns of 5 peptides. This structure is stable for more than 100 
ns. We modified the structure by pulling out residues 1–18 of the center amylin peptide, 
leaving a gap in the fibril, and inserted a rat amylin peptide in the simulation box such that it 
was bound to the displaced human peptide (Fig. 5a) in a parallel β-sheet conformation. 
Within 34 ns of starting the simulation, the human amylin β-strands translate to fill the gap 
caused by the missing N-terminus so that one β-sheet only has 4 strands while the other 
three have 5 strands. At no point in the simulation does the N-terminal strand reinsert itself. 
The inhibitor remains bound to the exposed human N-terminus and undergoes a structural 
change to form a partially ordered β-hairpin (Fig. 5b). This structure has not been observed 
in simulations of rat amylin monomers.33 Even though we have only one trajectory and the 
ratio of rat to human amylin is much lower than in the experiments, it is interesting that the 
human fibril appears to be quite stable even with a mismatched number of N-terminal and 
C-terminal β-strands. It is also interesting that the N-terminal residues of both human and rat 
amylin remain in a stable β-sheet conformation that could serve to template further β-sheet 
formation. Further simulations will be highly beneficial for better understanding the 
interactions between human and rat amylin, not only by providing better statistics, but 
because 2D IR spectra can now be quantitatively calculated from molecular dynamics 
trajectories29,34–36. By helping quantify structural disorder, molecular dynamics simulations 
will enable us to extract more specific structural information from the data.
CONCLUSIONS
Our results illustrate the complexity involved in the a priori design of peptide inhibitors, 
particularly designs based on amino-acid sequence6,7,9,10,37–39). Both the recognition and β-
blocking regions of rat amylin behave differently than expected, helping explain why rat 
amylin is only a moderate inhibitor of human amylin fibrils. The prolines residues do not 
prevent β-sheet formation by the human peptide, although they may slow the initial 
formation of β-structure. Indeed, the presence of three prolines ultimately prevents strong 
interactions with the C-terminal region, which could explain why rat amylin is a less-
effective inhibitor than similar peptides with just a single proline residue11,40. We also find 
that the recognition sequence in rat amylin ultimately forms its own amyloidogenic β-sheets 
that could potentially increase toxicity. Therefore, peptide inhibitor design must also account 
for possibly detrimental amyloid-inhibitor complexes. Another key observation is that 
significant structural rearrangements still occur after the system has apparently equilibrated 
as judged by thioflavin-T experiments. Thioflavin-T fluorescence is possibly the most 
commonly used method for assessing amyloid β-sheet content. Our results indicate that 
Thioflavin-T measurements alone do not always accurately reflect the structural kinetics.
Our 2D IR method is general and can be applied to a wide range of inhibitors and as well as 
other aggregation-prone peptides, such as Aβ26,41. By providing structural insight into the 
amylin-inhibitor complex, 2D IR fosters rational drug design efforts for improving the 
efficacy of peptide and peptide-mimic amyloid inhibitors. It is also complimentary to solid-
state NMR and X-ray studies of amyloid peptide fragments21,42, because 2D IR 
spectroscopy, while it offers less detailed structural information, provides a rapid method to 
obtain critical residue-specific information. 2D IR can also provide mechanistic information 
through kinetic studies27, which could be used to examine amyloid-inhibitor complexes 
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during the lag phase when oligomeric species are more prevalent. 2D IR spectroscopy can 
also be applied to membrane-bound systems32,35,43–47, which accelerate amylin aggregation 
in vitro. In cases where human aggregation diseases are caused by proteins, native chemical 
ligation can be used to 13C label segments or domains and the same strategy applied48. We 
also point out that the structural information reported here was all obtained using the 
diagonal peaks in the 2D IR spectrum. Thus, linear absorption spectra contain much of the 
same information. 2D IR spectroscopy has many benefits, such as the suppression of 
background absorbance, 2D lineshapes that give information about hydration29,35,45, and 
cross peaks that probe secondary structures25,49, but in principle the approach is available to 
any researcher with a standard FTIR spectrometer. Thus, both isotope-edited 1D and 2D IR 
spectroscopies can provide structural and mechanistic feedback to help understand and 
design amyloid inhibitors.
METHODS
Samples
All peptides were synthesized using solid-phase peptide synthesis and purified using HPLC, 
as previously described50,51. Amino acids labeled with 13C,18O isotopes were also prepared 
as previously reported51,52. Lyophilized peptides were dissolved to 1 mM concentration 
stock solutions in deuterated hexafluoroisopropanol. A portion of the stock solution was 
aliquoted, dried under nitrogen and then reconstituted in 5 µL of 20 mM phosphate D2O 
buffer solution (pD ~7.4) to initiate aggregation. The final total peptide concentration for 
samples containing pure human amylin was 1 mM and for samples containing equimolar 
human and rat amylin was 2 mM. Samples were prepared in the same manner for all 
experiments.
2D IR Measurements
2D IR spectra were measured and processed using methods previously described53. Briefly, 
60 fs (FHWM) mid-IR pulses were generated using a Ti:sapphire femtosecond laser system 
combined with an optical parametric amplifier. A mid-IR pulse shaping spectrometer54,55 
was used to collect the 2D IR spectra. Shot-to-shot phase cycling was performed to subtract 
scatter and collect data in the rotating frame. The probe signal was detected using a 64-
element linear MCT array and digitized on a shot-by-shot basis. The polarization of the 
pump pulses were set perpendicular to the probe pulse. Samples prepared for 2D IR 
experiments were immediately transferred to a CaF2 IR sample cell with a 56 µm Teflon 
spacer and kept under dry air to prevent hydrogen exchange from ambient water vapor.
Thioflavin-T Binding Kinetics
All fluorescence experiments were performed on an Applied Phototechnology fluorescence 
spectrophotometer using an excitation wavelength of 450 nm and an emission wavelength of 
485 nm. The excitation and emission slits were 5 nm. The fluorescence intensity was 
measured once a second for the human amylin only kinetics and once a minute for the 
human and rat amylin mixture. The data is presented without any averaging. Samples were 
prepared by in the same manner and concentration as for 2D IR measurements except that 
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the buffer solution also contains 16 µM thioflavin-T. A 1.0 cm cuvette was used and the 
samples were not stirred, as in 2D IR measurements.
Transmission Electron Microscopy
TEM was performed at the University of Wisconsin Medical School Electron Microscope 
Facility. Samples were initially prepared in the same manner and concentration as for 2D IR 
measurements. Then, for each sample, a 2 µL aliquot was loaded onto a pioloform-coated 
copper grid and stained with methylamine tungstate (Nanoprobes, Inc.). Excess stain was 
blotted off, and the sample was allowed to air dry. Images were acquired by using a Philips 
CM 120 microscope with an accelerating voltage of 80 kV.
Full methods and any associated references are available in the online version of this Article.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Sequence of human and rat amylin and structural model of human amylin fibrils
(a) Sequence of human and rat amylin, with 13C18O isotope labeled residues (red) and 
sequence differences (blue). (b) Depiction of a human amylin fibril viewed along the fibril 
axis with the sites of measured residues (spheres). The spheres are colored to summarize the 
labeled 2D IR spectra results shown in Figure 2b. Thus they show the effect of rat amylin on 
the inter-label coupling: bright red: ~100% loss of coupling, medium red: ~80% loss, light 
green: ~40% loss, medium green: ~35% loss, bright green: ~20% loss, grey: not 
measureable. (c) View of the fibril perpendicular to the fibril axis, with a label at a single 
residue shown (red spheres) in order to illustrate the formation of a linear chain.
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Figure 2. Rat amylin prevents human amylin from forming N-terminal, and not C-terminal, β-
sheets at 8 hours after mixing
2D IR spectra of 13C18O labeled human amylin. Top row: pure-labeled human amylin 
fibrils. Middle row: equimolar mixture of human and rat amylin. Bottom row: dilute-labeled 
human amylin fibrils. Each column of panels shows spectra with human amylin labeled at 
different residues: Ala13 (a–c), Leu16 (d–f), Ala25 (g–i) and Leu27 (j–l). Label features are 
highlighted with dashed rectangles and the label frequencies are marked with black vertical 
lines to highlight the shifts. The Ala13 and Leu16 label frequencies in the human-rat mixture 
closely match their respective dilute-labeled frequencies, showing that the rat peptide 
disrupts the β-sheet coupling at these residues. On the other hand, the Ala25 and Leu27 label 
frequencies are closest to their respective pure-labeled frequencies, showing that the β-sheet 
structure at these residues is largely intact. See Supplementary Figs. S1 and S3 for spectra of 
residues Ala5, Ala8, Ser20, Val32 and Gly33.
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Figure 3. Human amylin β-sheets, initially disrupted by rat amylin, eventually form and promote 
the formation of rat amylin β-sheets
(a) and (b), Possible structures of amylin-inhibitor complex. Ala13 isotope labels are shown 
as blue spheres. (a) Rat amylin (pink) prevents formation of the N-terminal β-sheet by 
human amylin (grey). (b) Rat and human amylin form mixed β-sheets. (c) Diagonal slices of 
unlabeled human and rat amylin mixtures. Rat amylin monomers added to preformed human 
amylin fibrils (red). (d) Diagonal slices through the unlabeled region of equimolar mixtures 
of human and rat amylin after 8 hours (black) and 24 hours (red). (e) 2D IR spectrum of 
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amylin-inhibitor complex with both human and rat amylin labeled at Ala13. (f) 2D IR 
spectrum of amylin-inhibitor complex with unlabeled human amylin and Ala13-labeled rat 
amylin. Rat and human amylin mixed as monomers and matured together (black). (g) 2D IR 
spectrum of Ala13-labeled human amylin after 24 hours in the presence of unlabeled rat 
amylin. (h) 2D IR spectrum of Ala13-labeled rat amylin after 24 hours in the presence of 
unlabeled human amylin. For e, f, g and h, the Ala13 feature was isolated by subtracting the 
corresponding unlabeled spectrum (see Supplemental for details).
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Figure 4. Electron microscopy supports the unexpected structural dynamics revealed by 2D IR 
results
TEM images of human and rat amylin mixture (a) after initial mixing, (b) at 8 hours, and (c) 
at 24 hours. (d) TEM image of human amylin at 24 hours. (a–d) Scale bars represent 100 
nm. Short, disordered structures are observed for the human-rat mixture at 8 hours while 
longer, fibril structures are observed at 24 hours. The fibrils observed in the human-rat 
mixture are thicker than human-only fibrils, suggesting the mechanism shown in panel e. (e) 
Rat (pink) and human (grey) peptides interact as monomers or early-stage oligomers. At 8 
hours, rat amylin prevents β-sheet formation for the region of human amylin containing 
residues Ala8, Ala13 and Leu16. At 24 hours, human amylin forms the N-terminal β-sheet 
and rat amylin forms ordered β-sheet structures templated by the human fibrils. Human 
Ala13 isotope labels are shown as blue spheres. (f) Schematic diagram of a human amylin 
fibril.
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Figure 5. Molecular dynamics simulation suggests that the N-terminals of human and rat amylin 
can form a partially ordered β-sheet complex
Human (grey) and rat (pink) amylin form a stable complex in which the N-terminal residues 
of both peptides are in a β-sheet conformation, which could promote formation of the rat 
amylin β-sheets detected in the 2D IR measurements. The N-terminal β-sheet of the fibril 
can close to heal the gap left by the extracted human N-terminus. (a) The starting 
configuration of simulation. (b) The configuration after 75 ns. The back half of the fibril 
model is lightened to clarify the structural changes in the front half.
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